20426-80-6

Usage

Uses

Used in Pharmaceutical Research and Development:
4-Chromancarboxylic acid is used as a key intermediate in the synthesis of various pharmaceuticals due to its unique chemical structure and potential biological activities. Its antioxidant and anti-inflammatory properties make it a valuable compound for the development of new drugs targeting a range of diseases.
Used in Organic Synthesis:
In the field of organic synthesis, 4-Chromancarboxylic acid serves as a versatile building block for the creation of complex organic molecules. Its reactivity and functional groups allow for a wide array of chemical reactions, facilitating the synthesis of diverse chemical entities.
Used in Antioxidant and Anti-Inflammatory Applications:
4-Chromancarboxylic acid is used as an antioxidant and anti-inflammatory agent for its potential therapeutic effects. Its ability to combat oxidative stress and reduce inflammation makes it a promising candidate for the treatment of conditions associated with these processes, such as neurodegenerative diseases and certain types of cancer.
Used in Cancer Therapy:
4-Chromancarboxylic acid is being studied for its potential therapeutic effects on cancer. Its biological activities suggest that it may have the capacity to inhibit cancer cell growth and proliferation, making it a candidate for further research and development in oncology.
Used in the Manufacture of Chemicals:
Beyond its pharmaceutical applications, 4-Chromancarboxylic acid also shows promise in the industrial production of various chemicals. Its unique structure and reactivity make it a valuable component in the synthesis of specialty chemicals and materials.

Upstream product

• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 
• 7677-24-9 trimethylsilyl cyanide 
• 113967-29-6 methyl chroman-4-carboxylate 
• 493-08-3 chromane 
• 124-38-9 carbon dioxide 
• 113967-32-1 4-Bromo-5,5-dimethoxy-2,3,4,5-tetrahydro-benzo[b]oxepine 
• 20426-78-2 4-bromo-3,4-dihydro-1(2H)-benzoxepin-5-one 
• 6786-30-7 3,4-dihydro-1-benzoxepin-5(2H)-one 
• 74187-63-6 4-((trimethylsilyl)oxy)chroman-4-carbonitrile 

Downstream Products

• 1401466-95-2 diethyl (R)-4-((R)-1-phenylallyl)chroman-4-carbonylphosphonate 
• 1343394-83-1 (rac)-chromane-4-carboxylic acid chloride 
• 1392493-59-2 N-(2-(pyrrolidin-1-yl)phenyl)chroman-4-carboxamide 

Relevant academic research and scientific papers

BCL-2 INHIBITOR

Disclosed herein is a compound of Formula (I) for inhibiting both Bcl-2 wild type and mutated Bcl-2, in particular, Bcl-2 G101V and D103Y, and a method of using the compound disclosed herein for treating dysregulated apoptotic diseases.

Photocarboxylation of Benzylic C-H Bonds

The carboxylation of sp3-hybridized C-H bonds with CO2 is a challenging transformation. Herein, we report a visible-light-mediated carboxylation of benzylic C-H bonds with CO2 into 2-arylpropionic acids under metal-free conditions. Photo-oxidized triisopropylsilanethiol was used as the hydrogen atom transfer catalyst to afford a benzylic radical that accepts an electron from the reduced form of 2,3,4,6-tetra(9H-carbazol-9-yl)-5-(1-phenylethyl)benzonitrile generated in situ. The resulting benzylic carbanion reacts with CO2 to generate the corresponding carboxylic acid after protonation. The reaction proceeded without the addition of any sacrificial electron donor, electron acceptor or stoichiometric additives. Moderate to good yields of the desired products were obtained in a broad substrate scope. Several drugs were successfully synthesized using the novel strategy.

DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS

Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

AMINOTRIAZOLE IMMUNOMODULATORS FOR TREATING AUTOIMMUNE DISEASES

1-Acyl-3-(heteroaryl)-1H-1,2,4-triazol-5-amines of formula (I) are disclosed. These compounds inhibit Coagulation Factor XIIa in the presence of thrombin and other coagulation factors. They are useful to treat autoimmune diseases.

HISTONE DEMETHYLASE INHIBITORS

This disclosure relates to compounds that inhibit histone demethylase activity. In particular, the disclosure relates to compounds that inhibit histone lysine demethylase KDM5B, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions disclosed herein.

N - (benzofuranol methyl ether - 5 - yl) benzopyran - 4 - amide used as fungicides

The invention relate to application of N-furan phenol methyl ether-5-yl) chromene-4-amide as shown in the chemical formulas I, II or III in specification in preparation of a sterilizing agent, wherein X1 is selected from hydrogen, C1-C2 alkyl, C3-C4 linear chain alkyl or C3-C4 branch chain alkyl, C1-C2 alkoxy, C3-C4 linear chain alkoxy or C3-C4 branch alkoxy; X2-X7 are selected from hydrogen, C1-C2 alkyl, C3-C4 linear chain alkyl or C3-C4 bran chain alkyl.

2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)

The use of a compound of formula (I): for the manufacture of a medicament for the treatment of conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1, also known as TRPV1).

Fused bicyclic carboxamide derivatives and methods of their use

Fused bicyclic carboxamide derivatives are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed.

NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS

The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action wherein each symbol is as defined in the specification. The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.

2-substituted-(2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1- yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 1. Effects of alkyl, arylalkyl, and diarylalkyl substitution

In this paper, we describe the synthesis of a series of α-substituted analogues of the potent and selective group II metabotropic glutamate receptor (mGluR) agonist (1S,1'S,2'S)-carboxy-cyclopropylglycine (2, L-CCG 1). Incorporation of a substituent on the amino acid carbon converted the agonist 2 into an antagonist. All of the compounds were prepared and tested as a aeries of four isomers, i.e., two racemic diastereomers. We explored alkyl substitution, both normal and terminally branched; phenylalkyl and diphenylalkyl substitution; and a variety of aromatic and carbocyclic surrogates for phenyl. Affinity for group II mGluRs was measured using [3H]glutamic acid (Glu) binding in rat forebrain membranes. Antagonist activity was confirmed for these compounds by measuring their ability to antagonize (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid-induced inhibition of forskolin-stimulated cyclic-AMP in RGT cells transfected with human mGluR2 and mGluR3. We found that while alkyl substitution provided no increase in affinity relative to 2, phenylethyl and diphenylethyl substitution, as in 105 and 109, respectively, were quite beneficial. The affinity of 109 was further enhanced when the two aromatic rings were joined by an oxygen or sulfur atom to form the tricyclic xanthylmethyl and thioxanthylmethyl amino acids 113 and 114, respectively. Amino acid 113, with an IC50 of 0.010 μM in the [3H]Glu binding assay, was 52-fold more potent than 2, whose IC50 was 0.47 μM.